🔎 Trials Near Me

Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Missouri › St. Louis

Qorannoo klinikaalii Kansaar Onnee Triple-Negative St. Louis, MO keessatti

Qorannoo 21 Kansaar Onnee Triple-Negative f St. Louis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Washington University Medicine, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Washington University School of Medicine in St. Louis, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06465069

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT06799065

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT04981119

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Namoota walitti qabaa jiraSadarkaa 3
  • Siteman Cancer Center ( Site 0099), St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06393374

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Namoota walitti qabaa jiraSadarkaa 3
  • Washington University Siteman Cancer Center ( Site 0031), St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06966700

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Local Institution - 0140, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06618287

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06657222

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Washington University School of Medicine, St Louis
  • Siteman Cancer Center-South County, St Louis
  • Siteman Cancer Center at Christian Hospital, St Louis
  • fi 1 dabalataa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT03606967

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Cancer Care Specialist of Illinois, O'Fallon · Miili 16 fagaatti
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07211178

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07029399

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Research Site, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT07115043

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Normunity Investigational Site, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Namoota walitti qabaa jiraSadarkaa 1
  • Washington University School of Medicine, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT07137416

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Mercy Hospital - South, St Louis
  • Mercy Hospital -STL, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT07327489

A Study of LY4175408 in Participants With Advanced Cancer

Namoota walitti qabaa jiraSadarkaa 1
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT07046923

Study of XB010 in Subjects With Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Siteman Cancer Center, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT06545331

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Siteman Cancer Center, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ama-2026 · NCT06926920

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ama-2026 · NCT05490472

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Namoota walitti qabaa jiraSadarkaa 1/2
  • Washington University, St Louis
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2025 · NCT06682793

Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti

Qorannoo biroo St. Louis keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.